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Pediatric slow progressors (PSP) are rare ART-naïve, HIV-infected children who maintain
high CD4 T-cell counts and low immune activation despite persistently high viral loads.
Using a well-defined cohort of PSP, we investigated the role of regulatory T-cells
(TREG) and of IL-7 homeostatic signaling in maintaining normal-for-age CD4 counts in
these individuals. Compared to children with progressive disease, PSP had greater
absolute numbers of TREG, skewed toward functionally suppressive phenotypes. As
with immune activation, overall T-cell proliferation was lower in PSP, but was uniquely
higher in central memory TREG (CM TREG), indicating active engagement of this subset.
Furthermore, PSP secreted higher levels of the immunosuppressive cytokine IL-10 than
children who progressed. The frequency of suppressive TREG, CM TREG proliferation,
and IL-10 production were all lower in PSP who go on to progress at a later time-point,
supporting the importance of an active TREG response in preventing disease progression.
In addition, we find that IL-7 homeostatic signaling is enhanced in PSP, both through
preserved surface IL-7receptor (CD127) expression on central memory T-cells and
increased plasma levels of soluble IL-7receptor, which enhances the bioactivity of
IL-7. Combined analysis, using a LASSO modeling approach, indicates that both
TREG activity and homeostatic T-cell signaling make independent contributions to the
preservation of CD4 T-cells in HIV-infected children. Together, these data demonstrate
that maintenance of normal-for-age CD4 counts in PSP is an active process, which
requires both suppression of immune activation through functional TREG, and enhanced
T-cell homeostatic signaling.
Keywords: pediatric HIV-infection, regulatory T cells (Treg), immune activation (IA), IL-7, homeostatic signaling,
pediatric slow progression, IL-10, immune regulation
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INTRODUCTION
In the absence of antiretroviral therapy (ART), HIV-infected
children typically progress rapidly to AIDS (1). “Pediatric
slow progressors” (PSP) are a subgroup of vertically HIV-
infected children who maintain their CD4 counts despite being
antiretroviral treatment-naive (2–7). These children share certain
fundamental immunological characteristics with the natural
hosts of nonpathogenic SIV infection such as sooty mangabeys,
including low immune activation on CD4 T-cells in the face
of persistent high viral loads (7–10). Here we investigate the
role of immune regulation by regulatory T-cells (TREG) and of
IL-7-mediated T-cell homeostasis, in maintaining this beneficial
phenotype in a well-described cohort of PSP (7).
Persistent immune activation is a hallmark of HIV infection
in humans and is an important driver of disease progression that
is independent of viral load (11–13). Indeed, in pediatric HIV
infection, it is CD4 T-cell activation and not viral load that is
the strongest predictor of CD4 decline (7, 13, 14). In the non-
human primate model of HIV infection, the rapid resolution of
immune activation during acute infection also distinguishes non-
pathogenic infection of SIV in sooty mangabeys from pathogenic
infection in rhesus macaques (15). In sooty mangabeys, this
resolution of immune activation is associated with an up-
regulation of the canonical TREG markers CD25 and FoxP3 on
CD4 and CD8 T-cells (16), and increased production of the
key regulatory cytokine IL-10 (17). Moreover, TREG numbers
in sooty mangabeys remain stable, whilst they are severely
depleted in rhesus macaques, in correlation with disease state
(18). The importance of TREG in pediatric non-progression has
not been assessed to date, but the similarities between PSP
and non-progressive SIV infection suggest a possible role for
these cells.
TREG are required to prevent autoimmunity and to
regulate over-reactive immunity in the setting of chronic
infections, including HIV infection (19–21). They can
exert their suppressive function through cell-cell contact
(22, 23), disruption of metabolic pathways (24), or by
releasing soluble suppressive factors like IL-10 or TGF-b
(25, 26) [reviewed in Yamaguchi et al. (27)]. TREG make
up ∼1% of CD4T cells in untreated HIV-infected adults,
but are more frequent in early life, and can constitute
up to 15% of total CD4 T-cells in the fetus (28). Their
frequency is inversely correlated with HIV-driven immune
activation (14, 29–34), and a decline in absolute TREG
numbers coincides with disease progression (14, 33, 35–
38). In addition, TREG have been shown to be comprised
of phenotypically and functionally diverse subsets. Miyara
et al. identified three phenotypically distinct subsets that
differed in their suppressive capacity: CD45RA+FoxP3lo
resting TREG cells and CD45RA
−FoxP3hi activated TREG
cells, both of which were suppressive in vitro, and a cytokine-
secreting CD45RA−FoxP3lo subset that did not display
suppressive activity in vitro. Terminally differentiated
activated TREG cells rapidly died whereas resting TREG cells
proliferated and converted into activated TREG cells in vitro and
in vivo (39).
In addition to TREG activity, non-progression in sooty
mangabeys has been linked to preservation of IL-7 signaling
in T-cells (40). This pleiotropic cytokine is crucial for the
development and homeostasis of T-cells, promotes antigen-
specific expansion and memory formation (41–44), and can
reverse T-cell exhaustion (45). Immune failure in both adult
and pediatric HIV infection is associated with perturbations in
IL-7 signaling (46, 47) and reduced responsiveness (48, 49). In
adult long-term non-progressors, IL-7R (CD127) expression is
preserved on central memory and effector memory CD4 T-cell
compartments when compared to untreated progressors (50).
Again, however, the importance of IL-7 to sustaining CD4 T-cell
levels in PSP remains unknown.
In this study, we investigate two mechanisms by which
PSP maintain their CD4 counts in the face of on-going
viral replication: first, via strong regulatory T-cell responses
that reduce immune activation; and, second, via intact IL-7
receptor signaling that preserves homeostatic proliferation. Both
mechanisms are interlinked by the main driver of pathogenesis
in HIV infection: chronic immune activation.
MATERIALS AND METHODS
Study Participants
Peripheral blood mononuclear cells (PBMC) and plasma of
vertically HIV-1C clade-infected children and age matched
healthy controls all from Southern Africa and predominantly
of Zulu origin, were obtained from clinics in Durban, South
Africa (Ithembalabantu Clinic and Prince Mshiyeni Hospital)
(see Table 1 for cohort characteristics). In the present study,
pediatric slow progressors (PSPN; n = 12) are defined as
vertically HIV-infected, ART-naïve, CD4 count >450/mm3 at
age >5 years. Pediatric future progressors (PFP; n = 11) were
meeting inclusion criteria for PSPN at the time point used for
the experiments but progressed in the longitudinal follow-up.
Pediatric progressors (PP; n = 10) are defined here as vertically
HIV-infected, ART-naïve, CD4 count<350/mm3 at age>5 years.
This pediatric cohort has been followed up for over 5 years.
Viral load measurement was performed using the COBRA
AmpliPrep/COBAS TaqMan HIV-1 Test version 2.0 by Roche
(CAP/CTMv2.0) (range, 20–10 millioncopies/ml) except at the
Ithembalabantu Clinic where the BioMérieux NucliSens Version
2.0 EasyQ/EasyMag (NucliSens v2.0) assay (range, 20–10million
copies/ml) was used.
Written informed consent was obtained for underage children
from their caregivers. Additionally, assent to participate in the
study was given directly by children in the appropriate age
groups. Studies were approved by the University of the Free State
Ethics Committee, Bloemfontein; Biomedical Research Ethics
Committee, University of KwaZulu-Natal, Durban; and Research
Ethics Committee, University of Oxford.
Sample Processing—PBMC and Plasma
Plasma was separated by centrifugation and crypopreserved
at −80◦C. Peripheral blood mononuclear cells (PBMCs) were
isolated by Ficoll density gradient centrifugation and stored in
liquid nitrogen until use.
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TABLE 1 | Clinical characteristics of study cohort.
Group n Age median
(IQR)
CD4/mm3 median
(IQR)
VL cp/ml median (IQR) ART baseline ART > baseline
Pediatric slow progressors total (PSP) 23 10.2 (7–13.1) 752 (450–906) 37,600 (6,200–88,000) no no/yes
PSP subsequently on treatment/ Future
progressors (FP)
11 12.4 (7–13.7) 704 (450–906) 59,000 (8000–130,000) no yes
PSP treatment naïve (PSPN) 12 9.85 (7.28–12.2) 796 (550–922.8) 24,000 (1015–57,000) no no
Pediatric progressors 10 10.65 (9–15.18) 233.5 (122.5–342.8) 120,000 (17,700–120,000) no yes
Pediatric healthy controls 20 13.15 (10–15.5) N/A N/A N/A N/A
Overview of study subjects used for the different experiments in this study. Not for all shown subjects all experiments could be performed. All HIV-infected paediatric individuals were
infected by vertical transmission.
N/A, not applicable.N/D, not done.
Flow Cytometry and ICS Assays
PBMCs were stained with fluorescent monoclonal antibodies
against markers previously associated with TREG / immune
activation /IL-7R (Supplementary Table 1). Briefly, cells were
thawed and rested in R10 medium overnight at 37◦C in 5%
CO2. For phenotyping cells were washed in 15ml of PBS,
centrifuged at 500 g for 5min and room temperature and the
supernatant removed. Cells were resuspended in a volume of
25 µl with titrated concentrations of fluorochrome-conjugated
monoclonal antibodies against cell surface markers and the L/D
fixable blue dead stain (Thermo Fisher Scientific) as a viability
marker (antibodies used are listed in Supplementary Table S1)
and stained for 20min in the dark. Cells were again washed x 2
in PBS and resuspended in Fix/Perm solution (ebioscience) for
intracellular staining (Ki-67, FoxP3) and incubated for 20min at
4◦C, followed by washing and incubating 20min in 20% Goat
serum for Fc-receptor blockade. Afterwards, cells were incubated
with intracellular antibodies for 20min at room temperature
in the dark, washed x 2 and the pellet was suspended in 2%
paraformaldehyde in PBS. For intracellular cytokine staining
assays cells were first stimulated with PMA/Ionomycin (at a
final concentration of 4 × 10−5M) in the presence of anti-
CD28 and anti-CD49 (1 mg/ml), Brefeldin A and Monensin (5
mg/ml) (BD biosciences), for 5 h, followed by surface staining
and intracellular staining as above. Rainbow beads were run
at every experiment and compensation adjusted to keep peaks
identical to ensure longitudinal comparability of experiments.
Flow cytometry acquisition was performed on a BD LSRFortessa
within 5 h of staining and analyzed using FlowJo version 9.9.5.
IL-7 and sCD127 Plasma Assays
Plasma levels of IL-7 and sCD127 were quantified using
commercially available enzyme-linked immunosorbent assay kits
(R&D Systems and Neobiolab, respectively) neat in duplicate.
Results are expressed in picograms per millilitre for IL-7 and
nanograms per millilitre for sCD127.
Statistical Analyses
Most statistical analyses were undertaken using Prism GraphPad
Software version 7.0. After confirming non-Gaussian distribution
within the majority of the parameters analyzed, Mann–Whitney
test was used to compare continuous factors between two groups
and Kruskal-Wallis test to compare continuous factors between
> two groups and Benjamini, Krieger and Yekutieli’s procedure
for false discovery rate to correct for multiple comparisons. For
paired analyses, Wilcoxon test was used and for paired analyses
at multiple time points 2-way ANOVA analyses. Bivariate
correlation analyses were performed using the Spearman rank
correlation method with exact permutation P-values calculated.
All P-values are two-sided, and a P-value of<0.05 was considered
significant. In scatterplots, median values, and interquartile range
are indicated.
The influence of several predictor variables (n = 39) on the
absolute number of CD4 T-cell counts was assessed by least
absolute shrinkage and selection operator (LASSO) principle (51)
on scaled covariates using the generalized linear model (GLM)
glmnet package of the statistical software R as described before
(7, 52). For this method, the optimal tuning parameter λ, which
reflects the amount of penalization and, hence, controls variable
selection, is determined via 5-fold cross-validation on the basis
of the model’s deviance. A final unregularized conventional GLM
(post-LASSO) is fitted on the selected set of covariates using the
R-function glm (Supplementary Figures 1A,B).
A correlation matrix was used to visualize Spearman’s
correlations between selected variables of the LASSO analysis,
comprising absolute CD4 T-cell count; viral load; frequencies
of HLA-DR, Ki-67, IL-7R expression on bulk CD4 and CD8
T-cells; HLA-DR and IL-7R expression on CM CD4 T-cells;
Ki-67 expression on CM TREG; frequencies of TREG TEMRA,
TREG EM, suppressive TREG, non-suppressive cytokine secreting
TREG, CD25
−CD127−CD4 T-cells; absolute count of TREG/µl;
as well as IL-10 production of TREG and CD4 T-cells upon
PMA/Ionomycin stimulation. A data set of n = 26 vertically
HIV-infected, ART-naïve children above 5 years of age for whom
all measurements were available from the same study visit was
used for analysis. Variables are grouped on the basis of principal
components analysis using the R package correlogram.
RESULTS
Pediatric Slow Progressors Display Low
General Immune Activation and
Proliferation
We defined pediatric slow progressors (PSP) as ART-naïve
children aged >5years whose absolute CD4 count is >450
cells/mm3. To examine the T-cell correlates of low immune
activation observed among PSP, we divided subjects into four
study groups: (i) Pediatric slow progressors, who maintained
CD4 counts at >450/mm3 throughout the study period and
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FIGURE 1 | Pediatric slow progressors show low immune activation preferentially on CD4 T-cells. CD4 count absolute (A), CD4 percentage (B), viral load (C) in three
pediatric groups: Pediatric slow progressors (PSP; n = 23) were defined here as treatment naïve, aged >5 years with CD4 counts >450/mm3 at the time point the
experiments were performed. According to the longitudinal follow up we separated “pediatric future progressors” (PFP; n = 11; light blue) who would go onto
treatment from true pediatric slow progressors, who stayed treatment naïve during the follow-up (PSPN; n = 12; dark blue). Pediatric progressors (PP; n = 10; red)
were defined as treatment naïve, aged >5 years with CD4 counts <350/mm3. For CD4:CD8 ratio (D) age-matched uninfected controls (n = 20; green) were included
as control group. (E) Frequency of HLA expression and its correlation with CD4 percentage (F) on CD4 T-cells within the 4 pediatric groups. (G,H), same as (E,F) but
for Ki-67 expression. (I–L) same as (E–H) but of CD8 T-cells. For scatterplots, median, and interquartile range are shown. Kruskal-Wallis test was performed and
corrected for multiple comparisons. Only significant p-values (<0.05) are given. For correlations, Spearman ranks test was used. For correlations with CD4
percentage, all HIV-infected infants were used including those not fulfilling criteria for PSP nor PP (black dots; n = 3; CD4 count >350 and <450/mm3).
remained ART-naïve (PSPN; n = 12); (ii) Pediatric future
progressors (PFP; n = 11): children who met the criteria to
be categorized as PSP at baseline, but who later experienced
CD4 decline to <350 cells/mm3 and commenced ART (iii)
Pediatric progressors (PP; n = 10), defined as being ART-
naïve with CD4 <350/mm3 who commenced treatment after
the blood draw; (iv) Age-matched HIV-uninfected children (n
= 20). The absolute CD4 counts, CD4 percentage, CD4:CD8
ratios and viral loads are shown in Figures 1A–D and clinical
features summarized in Table 1. As previously reported (7),
CD4 T-cell activation, measured by HLA-DR expression, was
lower in both PSPN and PFP compared to PP and correlated
with disease progression by CD4% (Figures 1E,F). CD4 T-
cell proliferation, measured by Ki-67, also correlated very
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FIGURE 2 | Suppressive regulatory T-cells are increased in pediatric slow progressors. (A) Absolute TREG count/µl (gated on CD25
+FoxP3+ CD4 T-cells) within the
different pediatric groups: PSPN (dark blue; n = 12), PFP (light blue; n = 11), PP (red; n = 10) and (B) its correlation with HLA-DR and Ki-67 (C) on CD4 T-cells. For
correlations all HIV-infected children were used including those not fulfilling criteria for PSP nor PP (black dots; n = 3; CD4 count >350 and <450/mm3 ). (D) Gating
strategy for three functional TREG (gated of CD25
+FoxP3+ CD4 T-cells) memory subsets (39): (i) “activated”-suppressive TREG (CD45RA
−FoxP3high; gray); (ii)
“resting”-suppressive TREG (CD45RA
+FoxP3low; orange) and cytokine-producing non-suppressive TREG (CD45RA
−FoxP3low; pink). (E) Same groups as (A) but
including uninfected controls (green; n = 20) and showing the frequency of “resting”- suppressive TREG (CD45RA
+FoxP3low) and cytokine-producing
non-suppressive TREG (CD45RA
−FoxP3low; F). (G) Same as (E,F) but showing the ratio of all suppressive TREG (CD45RA
+FoxP3low and CD45RA−FoxP3high;
orange and gray population, respectively) to non-suppressive TREG (CD45RA
−FoxP3low; pink population) within the pediatric groups. For scatterplots, median, and
interquartile range are shown. Kruskal-Wallis test was performed and corrected for multiple comparisons. For correlations, Spearman ranks test was used.
strongly with CD4%, but unlike HLA-DR, was significantly
higher on PSPN and PFP compared to healthy controls
(Figures 1G,H). The pattern of HLA-DR expression is similar
on CD8 T-cells, but Ki-67 expression does not distinguish
between progressors non-progressors (Figures 1I–L). These data
in a subset of the pediatric cohorts previously described (7)
confirm the previous findings showing low immune activation
and, additionally, low proliferative activity on CD4 T-cells of
PSP, both of which are strongly linked to CD4 count in ART-
naïve children.
Suppressive Regulatory T-Cells Are
Increased in Pediatric Slow Progressors
To determine whether TREG play a role in controlling immune
activation in these children, we studied CD4T-cells co-expressing
CD25 and the canonical transcription factor FoxP3 (39, 53)
in the pediatric study groups described. The absolute number
of TREG was significantly elevated in both PSPN and PFP
(Figure 2A), and this correlated negatively with HLA-DR and
Ki-67 expression on CD4 T-cells (Figures 2B,C), consistent with
a role for TREG in preserving low immune activation in PSP.
A similar trend was observed for TREG frequency, although
statistically not significant (Supplementary Figure 2).
To investigate whether these differences in TREG numbers
between the pediatric study groups might correspond with
functional differences, we examined TREG phenotype using
expression levels of CD45RA and FoxP3 to identify three
previously defined distinct functional TREG subsets: (1)
CD45RA+ve FoxP3lo resting TREG (Figure 2D; orange
population), (2) CD45RA-ve FoxP3hi activated TREG cells
(Figure 2D; gray population), both of which are suppressive
in vitro; and (3) CD45RA-ve FoxP3lo TREG that secrete
cytokines but have no direct immunosuppressive activity
(Figure 2D; pink population) (39). No significant differences
between the study groups were observed in the frequency of
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FIGURE 3 | Memory TREG proliferation and IL-10 secretion are increased in pediatric slow progressors. (A) Frequency of Ki-67+ve “central memory” TREG (gated on
CD4+CD25+FoxP3+CD45RA−CCR7+) within the pediatric groups: PSPN (dark blue; n = 12), PFP (light blue; n = 11), PP (red; n = 10), and uninfected controls
(green; n = 20). (B) Exemplary FACS plot of one PSPN study subject showing CD4 (x-axis) vs. IL-10 (y-axis) staining (left: unstimulated control, right: stimulated with
PMA/Ionomycin). (C) Same groups as (A) but showing IL-10 production of CD4 T-cells as measured by intracellular staining assay after 5 h stimulation with PMA/
Ionomycin and (D) its correlation with CD4:CD8 ratio within the whole pediatric cohort. (E) Same as (C) but of TREG. (F) Same as (D) but correlating IL-10 production
of CD4 T-cells with Ki-67 expression on CD4 (left) and CD8 (right) T-cells. For correlations, all data available from pediatric subjects was used, including those not
fitting criteria for PSP nor PP. For scatterplots, median, and interquartile range are shown. For correlations, Spearman ranks test was used. Kruskal-Wallis test was
performed and corrected for multiple comparisons.
CD45RA-ve FoxP3hi activated TREG (data not shown). However,
CD45RA+veFoxP3lo resting TREG (a functionally suppressive
subset) were significantly higher in PSP compared to PP
(Figure 2E), whilst non-suppressive, CD45-ve FoxP3lo TREG,
were highest in PP (Figure 2F). Together, the overall ratio of
suppressive (combining the resting CD45+veFoxP3lo and the
activated CD45RA-ve FoxP3hi subset): non-suppressive TREG
is higher in PSPN compared to both PP and PFP (Figure 2G).
Overall these data suggest TREG are both expanded and more
functional in PSP compared to PP.
Memory TREG Proliferation and IL-10
Secretion Are Increased in Pediatric Slow
Progressors
To further investigate TREG activity, we next measured
proliferation and production of the key anti-inflammatory
cytokine, IL-10 (27). Much higher levels of ex-vivo proliferation,
by Ki-67, were observed in the central memory TREG subset
of PSPN, compared to both PP and PFP (Figure 3A, see
Supplementary Figure 3A for exemplary gating plots).
Importantly, this was highly specific to central memory TREG,
and not observed on central memory CD4 T-cells, on total TREG,
or on total CD4s (Supplementary Figure 3B, Figure 1G). These
data are consistent with the hypothesis that the expanded and
phenotypically functional TREG observed in PSP, are maintained
through active, on-going proliferation in these subjects, and that
this activity is required to reduce immune activation and prevent
CD4 T-cell decline.
Evidence of this on-going immune regulation in PSP
was also observed when we measured IL-10 production
(Figure 3B). In response to non-specific stimulation with
PMA/ionomycin, IL-10 production was severely impaired
in PP, but preserved in PSPN (p = 0.01, Figure 3C). Again,
PFP display an intermediate phenotype, and overall IL-10
production correlated with immune health, as measured
by CD4:CD8 ratio (Figure 3D). As previously reported
(54) IL-10 production by TREG themselves was low, but
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FIGURE 4 | Increased IL-7/sIL-7 receptor in pediatric slow progressors. Frequency of IL-7R (CD127) expression on CD4 (A) and on central memory CD4 (B) T-cells in
PSPN (dark blue; n = 10), PFP (light blue; n = 8), PP (red; n = 8), and uninfected pediatric controls (green; n = 15). (C) Same groups as before but showing frequency
of IL-7R expression on CD8 T-cells and (D) frequency of CD4 T-cells double-negative for IL-2R (CD25) and IL-7R (CD127). (E) Ex-vivo plasma levels of IL-7 in pg/ml in
PSPN (n = 13, dark blue), PFP (n = 6, light blue), PP (n = 12; red), and pediatric uninfected controls (n = 14; green). (F) Same as in (E) but showing plasma levels of
IL-7R (sCD127) in ng/ml in the different groups. For scatterplots, median, and interquartile range are shown. Kruskal-Wallis test was performed and corrected for
multiple comparisons.
remained elevated in PSPN compared to PP (Figure 3E).
Overall, total IL-10 production by CD4 T-cells within all
pediatric study subjects correlated inversely with Ki-67
expression in both bulk CD4 and CD8 T-cells (Figure 3F),
consistent with a direct role for this cytokine in limiting
immune activation. Taken together, these data suggest
that the maintenance of CD4 T-cells in PSP is an active
process, impairment of which, as in PFP, may precipitate
disease progression.
Increased IL-7/ sIL-7 Receptor in Pediatric
Slow Progressors
Having established a role for immune regulation in PSP, we
next examined the importance of homeostatic IL-7 signaling in
these individuals. CD4 T-cell depletion in adult HIV infection
is associated with a loss of the IL-7 receptor, CD127, whilst
both non-progressing adults, and SIV-infected sooty mangabeys
maintain high CD127 expression (40, 55, 56). Consistent
with these data, we find CD127 is reduced on CD4 T-
cells from PP compared to uninfected controls (p = 0.001)
but preserved in both PSP groups (p = 0.01; Figure 4A).
This is primarily a result of reduced expression on central
memory T-cells (Figure 4B) and not in other memory subsets
(Supplementary Figure 4). Interestingly, CD127 expression on
CD8 T-cells is significantly lower in all HIV-infected individuals
compared to healthy controls, irrespective of disease progression
(Figure 4C). Furthermore, with respect to homeostatic T-
cell proliferation mediated by IL-2 signaling via the high
affinity IL-2 receptor CD25, we observed that CD25 CD127
double negative CD4 T-cells are expanded in PP compared
to healthy controls, but not in PSP (Figure 4D). This finding,
among HIV-infected children, is also consistent with the
association in adults described between an expansion of
CD4 T-cells lacking both CD25 and CD127 and progressive
disease (55).
As CD4 T-cells are a main consumer of IL-7 in vivo, loss of
these cells in progressive adult HIV infection has been linked
with an increase in plasma levels of IL-7 (43). Thus, IL-7
itself is considered unlikely to be a limiting resource in HIV
infection. However, recent data demonstrate that the bio-activity
of IL-7 is directly enhanced by the presence of soluble CD127
(sCD127) (57). Indeed, the positive benefit of IL-7 therapy in
SIV infected rhesus macaques was dependent on high levels
of sCD127 (58). We therefore measured plasma levels of IL-
7 and sCD127 in HIV-infected children. As expected, plasma
IL-7 was not limiting in any of our designated groups, and
indeed no significant differences were observed (Figure 4E).
However, sCD127 levels were markedly higher in PSP (median
212 ng/ml) compared to both PP (154 ng/ml), and uninfected
controls (142 ng/ml; p = 0.009). As reported elsewhere, plasma
level of sIL-7R are far greater than that of IL7 itself, being
in the 100–400 ng/ml range compared to 1–30 pg/ml for IL-7
[Figure 4F; (57, 59)]. Importantly, the fact they have significantly
higher levels of sCD127 than healthy controls, again suggest
that this is an active process in PSP, rather than a bystander
effect of non-progression. Together with preserved expression
of the surface receptor CD127, IL-7 signaling in PSP is
likely to be enhanced by high levels of sIL-7R in plasma,
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TABLE 2 | Association of immunological parameters with CD4 T-cell count.
Variable Lasso estimate Post-lasso estimate p-value
CD4+Ki67+ −0.180 −0.265 < 0.0001
CD4+CM HLA-DR+ −0.033 −0.156 < 0.0001
CD4+CD25-CD127- −0.095 −0.117 < 0.0001
Treg count 0.069 0.111 < 0.0001
CD8+CD127+ 0.032 0.063 < 0.0001
Treg EM −0.026 −0.057 < 0.0001
Viral load −0.007 −0.046 0.0002
Non-suppr Treg −0.003 −0.044 0.002
CD4+HLA-DR+ −0.059 −0.025 0.133
Standardized regression parameter estimates for the selected set of covariates by an
unregularized conventional GLM (post-LASSO) using the R-function glm are shown
in the middle two columns. In the right column the calculated p-value is shown.
However, it has to be mentioned that the p-values and significance statements obtained
from the post-LASSO analysis should be regarded with caution. In general, these
values tend to underestimate the overall level of uncertainty in the estimates, as the
uncertainty from the preceding LASSO procedure is ignored. Following covariates were
included into the LASSO analysis but not selected and, hence, are not displayed in
the table: Age, CD8+HLA-DR+, CD8+Ki-67+, TREG frequency, TREG memory subsets
other than EM, TREGKi-67
+, TREG EmraKi-67
+, CD4+ IL-10, and TREG IL-10 production in
response to PMA/Ionomycin, CD4+CD127+, CD4+ memory subsets CD127+, HLA-DR+
and Ki-67+, suppressive-activated TREG, suppressive-resting TREG, plasma IL-7, and
sCD127.Selected regression parameter estimates with LASSO approach implemented
in the R package glmnet are shown in the left column in HIV-infected children (n = 26)
with available data for all regarded parameters.
to potentiate the homeostatic activity of IL-7, and preserve
CD4 counts.
Preservation of IL-7Ra and IL-2Ra
Expression on CD4 T-Cells and TREG Count
Are Independent From Immune Activation
and Strong Associates for Slow
Progression in Pediatric HIV Infection
To determine the independent contribution of the
multiple, often correlated parameters (see correlogram,
Supplementary Figure 5) described to the maintenance of
normal-for-age CD4 T-cell counts, we assessed the influence
of each using a generalized linear model (GLM), applying
the least absolute shrinkage and selection operator (LASSO)
principle on scaled covariates as described before (Table 2) (7).
In agreement with this previous study, a primary driver of slow
progression in this current analysis is low immune activation on
CD4 T-cells. However, Ki-67 expression on CD4 T-cells, which
was not included in the previous analysis, supersedes HLA-DR
expression on CM CD4 T-cells, previously identified as the
strongest predictor of CD4 count. In addition to these markers
of immune activation, the LASSO model, also identifies IL-7R
(CD127) and IL-2R (CD25) expression on CD4 T-cells, IL7-R
of CD8 T-cells, as well as absolute TREG count and phenotype,
as making independent contributions on CD4 count. Taken
together, these data strongly support an important role for
an active TREG response and T-cell homeostatic signaling in
maintaining normal-for-age CD4 counts in PSP.
DISCUSSION
In this study, we investigate the underlying mechanisms of CD4
preservation in a well-defined cohort of HIV-infected pediatric
slow progressors (PSP). These children share fundamental
characteristics with the natural hosts of non-pathogenic SIV
infection, most importantly the preservation of circulating CD4
T-cells, and the lack of immune activation, despite on-going viral
replication. Here we find strong evidence that the maintenance
of this non-progressive state is an active process, requiring both
immune regulation via TREG activity and IL-10 production, and
enhancement of homeostatic IL-7 signaling. Notably, we also
observe differences in phenotype and TREG activity between PSP
who remain stable through the course of study (PSPN) and
those who go onto progress at a later time-point (PFP). This
suggests that TREG activity is particularly important in preventing
progression, and that loss of this key function will precipitate
development of disease. Moreover, this observation strengthens
the argument that active involvement of TREG is required to
maintain non-progression in PSP, rather being a consequence of
a preserved CD4 T-cell compartment.
The role of regulatory T-cells in HIV infection has been
controversial, with some studies suggesting they are detrimental
as they inhibit antiviral T-cell responses (60–62), whilst others
find a beneficial role through the reduction of immune activation
(63–66) [reviewed in Phetsouphanh et al. (67)]. However, in
general, preservation of TREG has been associated with positive
outcomes; including non-progression in HIV elite controllers
(68, 69), adult viremic slow progressors (70) and natural hosts of
SIV infection (71). Conversely, a loss of circulating TREG in adult
progressors inversely correlates with the activation and apoptosis
of CD8 T-cells (72), and experimental depletion in SIV-infected
natural hosts increases immune activation and viral replication
(73). The importance of measuring absolute counts has been
emphasized previously (14, 35), in studies finding that the relative
frequency of TREG was increased in all HIV-infected individuals,
compared to controls, but that the absolute number was greatly
decreased, with the exception of elite controllers. Taken together,
these studies strongly suggest TREG can play a beneficial role in
limiting HIV disease progression.
Our hypothesis that activation of TREG in PSP is an important
indicator of their functional involvement in immune regulation
is supported by previous work showing adult HIV-infected elite
controllers (EC) and viremic long term non-progressors (LTNPs)
have more activated TREG than healthy controls (74). Moreover,
similar to our PSP, these EC have preserved IL-10 production in
contrast to the controls. IL-10 is an anti-inflammatory cytokine
that is critically important in preventing inflammatory and
autoimmune diseases and is produced by multiple cells of the
adaptive immune system including CD4 T-cells and TREG as well
as by innate cells [reviewed in Kwon and Kaufmann (54)]. Not
all studies have shown a positive effect of IL-10 in adult HIV
infection (75, 76) due to its negative impact on HIV-specific
T-cell proliferation and effector function. It is possible that IL-
10 has different effects in adult and pediatric HIV infection, as
cytotoxic T-cells are not thought to be important in PSP (77).
However, other studies have shown a correlation between IL-10
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production, low immune activation, and slow disease progression
in adult HIV infection (78) and genetic polymorphisms in the
IL-10 promoter that are associated with higher IL-10 production
have been shown to attenuate CD4 T-cell loss in HIV-infected
individuals (79–81).
In addition to immune regulation, a key observation of
our study is the apparent preservation and augmentation of
IL-7 signaling in PSP. Firstly, and in contrast to progressing
children, IL-7 receptor expression (CD127) is preserved in PSP,
especially within the CD4 T-cell compartment. This correlates
with parameters of disease progression and is in accordance
to various studies of adult and pediatric HIV infection (50,
82–86). Notably, differences in CD127 expression are most
prominent within the central memory compartment, which
has recently been shown to be particularly dependent on IL-
7 signaling (87). Similar preservation of CD127 expression in
the central memory compartment has been described in adult
elite controllers and LTNP (50, 88). In these studies, CD127
expression was directly linked to viral load, which cannot be true
in the case of PSP, who are all viremic, again highlighting the
likely differences inmechanism underlyingHIV non-progression
in adults and children.
Second, and most unexpectedly, we found PSP had increased
plasma levels of sCD127 compared to PP and healthy controls.
The precise details of how sCD127 influences IL-7 signaling and
T-cell homeostasis are unclear. Progressive adult HIV infection
was linked to increased plasma levels of sCD127, hypothesized
to inhibit IL-7 availability (59). However, lower levels of sCD127
have been observed by others in HIV-infected patients compared
to healthy controls (89). Moreover, higher levels of sCD127 in
plasma were associated with improved immune reconstitution
in SIV infected rhesus macaques treated with recombinant IL-
7 (58). The potentiating effect of sCD127 on IL-7 signaling
is supported by mechanistic studies showing it enhances the
bioactivity of IL-7 when the cytokine is limiting, as it is presumed
to be the situation in-vivo (57, 59). Therefore, we hypothesize
that increased plasma sCD127 leads to enhanced bioactivity of
IL-7 in PSP and, along with preserved surface CD127 expression,
improves maintenance of CD4 T-cells through IL-7 homeostatic
signaling. The fact that sCD127 levels are higher in PSP than
healthy controls, suggests this is an important mechanism in
preserving CD4 T-cell levels in these rare PSP individuals.
One potential limitation of this study is the use of surface
CD25 as a marker of TREG, as this molecule is also an
activation marker, whose expression may be affected by HIV-
driven immune activation (90, 91). However, we have previously
examined CD25 in HIV-infected and uninfected children and
did not observe a significant impact of HIV on overall CD25
expression levels on CD4 T-cells (92). Furthermore, as the PSP
group displayed very low immune activation, it is unlikely to
have caused elevated CD25 expression within this group. An
additional limitation is the lack of in vitro data to directly
determine TREG activity (39). Unfortunately, we did not have
sufficient samples remaining from this historical cohort to
perform such assays. However, the fact that we have identified
multiple independent measures of enhanced TREG activity in
PSP, including increased TREG frequency and proliferation,
TREG skewing toward more suppressive phenotypes, and
enhanced IL-10 production, strongly supports the existence
of enhanced TREG suppressive capacity in the unique subset
of PSP.
In this study, we observed various mechanisms contributing
to CD4 T-cell preservation shared between PSP and the natural
hosts of SIV infection. Firstly, as observed in natural hosts (8, 10,
16), PSP had low T-cell immune activation and proliferation as
measured by HLA-DR and Ki-67 expression despite viremia and
this correlated inversely with parameters of disease progression.
Secondly, PSP showed increased absolute TREG numbers and
this was strongly inversely associated with immune activation
(18). Thirdly, both CD4 T-cells and TREG of PSP secreted more
IL-10 than those of progressors which fits with the observation
that in African green monkeys, but not in rhesus macaques,
SIV infection leads to expression of an anti-inflammatory profile
including IL-10, and TGF-β secretion and an increase in TREG
(17). And lastly, both PSP and natural hosts have a low frequency
of CD4 T-cells lacking both IL-7R and IL-2R (CD127 and CD25)
(55). These CD127-veCD25-ve CD4 T-cells show features of
activated effectors and could therefore be key promoters of
the overall level of immune activation and disease progression
(55). LASSO modeling suggests that, although some of these
parameters maybe linked through immune activation, both TREG
activity and T-cell homeostasis are independently involved in
maintaining CD4 counts in PSP.
Over all, our findings support a model where PSP preserve
their CD4 T-cells through actively maintaining low immune
activation, requiring both immune regulation via TREG activity
and IL-10 production, and enhancement of T-cell homeostatic
IL-7 signaling.
AUTHOR CONTRIBUTIONS
JR designed the study, conducted experimental work within the
study, analyzed the data, and wrote the paper. AN, MM, and EA
conducted experimental work within the study. AG performed
statistical analyses within the study. TN supervised experimental
work within the study. HK, PG, and AL supervised experimental
work within the study, analyzed data, and wrote the paper. PG
established research cohorts.
FUNDING
AL: WT and HHMI; PG: WT (Grant 104748MA) and NIH (RO1
AI133673); HK: WT (Grant 202485/Z/16/Z).
ACKNOWLEDGMENTS
We thank all children and their care givers for their time
and commitment to this study. We also thank all staff
at the Ithembalabantu Clinic in Umlazi, Durban, for their
essential support and all core staff members at the HIV
Pathogenesis Programme who helped with patient recruitment
and sample processing.
Frontiers in Immunology | www.frontiersin.org 9 February 2019 | Volume 10 | Article 213
Roider et al. Increased Treg in PSP
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.00213/full#supplementary-material
Supplementary Figure 1 | (A) LASSO coefficient paths vs. tuning parameter λ
and (B) deviance of the model via 5-fold cross-validation.
Supplementary Figure 2 | Frequency of TREG (%CD25
+FoxP3+ of CD4 T-cells)
in PSPN (dark blue; n = 12), PFP (light blue; n = 11), PP (red; n = 10) and
uninfected pediatric controls (green; n = 20).
Supplementary Figure 3 | (A) Exemplary gating strategy for Ki-67 expression of
“central memory” TREG (CD4+CD25+FoxP3+CD45RA−CCR7+) in one PSPN
(blue; top row) and one PP child (red; bottom row). (B) Frequency of Ki-67
expression on all TREG (gated on CD4+CD25+FoxP3+; left), of all central
memory CD4 T-cells (CD45RA-CCR7+; CM; middle) and of Ki-67 expression on
all CM T-cells (CD45RA−CCR7+; right) within the different pediatric groups: PSPN
(dark blue; n = 12), PFP (light blue; n = 11), PP (red; n = 10) and uninfected
pediatric controls (green; n = 20). Kruskal-Wallis test was performed and
corrected for multiple comparisons.
Supplementary Figure 4 | Frequency of IL-7R expression on naïve (TN; left),
effector memory (EM; middle) and terminally differentiated (Temra; right) CD4
T-cells in PSPN (dark blue; n = 12), PFP (light blue; n = 11), PP (red; n = 10) and
uninfected pediatric controls (green; n = 20). For scatterplots, median and
interquartile range are shown. Kruskal-Wallis test was performed and corrected for
multiple comparisons.
Supplementary Figure 5 | Correlation matrix in ART-naïve HIV-infected children
(n = 25) with available data for all regarded parameters. Positive correlations are
colored in blue and inverse correlations in red with deeper color shading and
bigger circle size reflecting stronger r-values. Correlations with p > 0.05 are
left blank.
Supplementary Table 1 | List of antibodies for flow cytometry.
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